OPINION ARTICLE

NMDA receptor modulation and severe acute respiratory syndrome treatment [version 1; peer review: 2 approved]

Blaise M. Costa

Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24060, USA

V1 First published: 18 Oct 2021, 10(Chem Inf Sci):1060
<https://doi.org/10.12688/f1000research.73897.1>Latest published: 18 Oct 2021, 10(Chem Inf Sci):1060
<https://doi.org/10.12688/f1000research.73897.1>

Abstract

N-Methyl-D-aspartate (NMDA) subtype of glutamate receptors is expressed in the human lungs and central nervous system. NMDA receptor potentiation could increase calcium ion influx and promote downstream signaling mechanisms associated with cellular contractions that are disrupted in severe acute respiratory syndrome. Pharmacological effects generated by triggering glutamate receptor function in the brain, coupled with concurrent stimulation of the respiratory tract, may produce a synergetic effect, improving the airway smooth muscle function. A novel multipronged intervention to simultaneously potentiate NMDA receptors expressed both in the central nervous system and airway muscles would be helpful for the treatment of severe acute respiratory syndrome that deteriorates peripheral and central nervous system function before causing death in humans.

Keywords

NMDA, severe respiratory syndrome (SARS), GluN2D, Potentiator

Open Peer Review

Approval Status

	1	2
version 1
18 Oct 2021	view	view

1. **James Pearle**, California Research Medical Group, Fullerton, USA

2. **Jaewon Ko** , Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Chemical Information Science** gateway.

Corresponding author: Blaise M. Costa (bcosta@vcom.vt.edu)

Author roles: Costa BM: Conceptualization, Resources, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The NMDA receptor potentiation research work was funded by American Heart Association Scientist Development Grant to BMC.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Costa BM. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Costa BM. **NMDA receptor modulation and severe acute respiratory syndrome treatment [version 1; peer review: 2 approved]** F1000Research 2021, 10(Chem Inf Sci):1060 <https://doi.org/10.12688/f1000research.73897.1>

First published: 18 Oct 2021, 10(Chem Inf Sci):1060 <https://doi.org/10.12688/f1000research.73897.1>

Glutamate is the major neurotransmitter of the central nervous system and it has diverse roles in the periphery. The N-methyl-D-aspartate (NMDA) receptor is a major subtype of glutamate receptors, which are predominantly expressed throughout the nervous system and in all vital organs in the human body.¹ Functional NMDA receptors are heterotetramers composed of two identical glycine binding GluN1 subunits and two identical or different glutamate binding GluN2 subunits, of which there are four subtypes, GluN2A-D.^{2,3}

Expression of NMDA receptors in the human lungs

The Human Proteome Project identified abundant expression of NMDA receptor subunits in various organs outside the CNS, including lungs, esophagus, and T-helper cells.¹ This finding corroborates a large number of previous reports on the extraneuronal expression of NMDA receptors in various animals.^{1,4–12} NMDA, when applied to perfused tracheal segments of guinea pigs, increased resting muscle tone and enhanced the contractile response to acetylcholine.^{13,14} In whole guinea pig lungs, when administered through the trachea, NMDA increased airway perfusion pressure and this increase was abolished by NMDA receptor channel blocker MK-801(4). Following systemic MK-801 administration, adult cats developed apneusis.^{15,16} In addition, recent studies reveal the critical role of endogenous glutamate in NMDA receptor function during acute lung injury and airway inflammation.^{4,14,17,18} An NMDA receptor blocker could impair fetal rat lung development.^{19,20} NMDA receptor activation mediates lung fibroblast proliferation and differentiation in hyperoxia-induced chronic lung disease in newborn rats.²⁰ Acute lung injury, acute respiratory distress syndrome and severe acute respiratory syndrome (SARS) all imply the occurrence of lung injury resulting from direct or indirect respiratory insult.²¹

The expression of GluN1/2A and 1/2B subtypes were not confirmed in the lung cells, whereas the GluN1/2C subtype was found to be expressed in peripheral and middle-lobe lung samples.⁴ The GluN1/2D subunit was predominantly expressed in the peripheral, gas-exchange zone of the lungs and in alveolar macrophages; this expression was upregulated in lungs treated with NMDA.⁴ GluN1 and all four GluN2 subunits were also expressed in the human pulmonary artery smooth muscle cells.²² Overall, these findings indicate that NMDA receptors could control the respiratory tract function in vertebrate animals.²³

Kinetics of NMDA receptor subtypes

Glutamate, with concurrent binding of the co-agonist D-serine or glycine, activates NMDA receptors that non-selectively conduct ions across the cells at depolarizing membrane potential which unbinds the otherwise blocking Mg^{2+} ions. NMDA receptor mediated transport of calcium and sodium ions into the cytoplasm is essential for excitatory cellular events that result in human airway smooth muscle contraction.²⁴ Each non-GluN1 subunit confers distinct spatiotemporal expression and biophysical properties that result in varying agonist affinity, magnesium sensitivity, ion conductance, activation kinetics, open probability, mean open time, cellular localization, and downstream signaling mechanisms.² In general, diheteromeric NMDA receptors (GluN1/2) exhibit deactivation time constants that span about a 50-fold range, with the following order (from fastest to slowest): NR2A < 2C < 2B << 2D.²⁵ The GluN1/2A subunit-containing NMDA receptor deactivation time constant is about ~50 ms, GluN1/2B ~400 ms, GluN1/2C ~290 ms and GluN1/2D is >1second.²⁵ Since GluN1/2C&D subunits of NMDA receptors are predominantly expressed in the lung epithelial cells and macrophages, and are the slowest channel (among other glutamate receptors) to deactivate, these receptors can conduct a large amount of calcium and sodium ions into the cells and trigger cellular contractions.^{25–27}

Antiviral properties of drugs acting on NMDA receptors

One of the clinically used antiviral agents, amantadine, is a potent NMDA receptor antagonist.²⁸ This drug is also an FDA-approved drug of choice (brand name, Gocovri®) for the treatment of dyskinesia in patients with Parkinson's disease. An analog of amantadine, memantine (brand name, Namenda®), is one of two FDA-approved clinically used drugs for the treatment of moderate to severe symptoms of Alzheimer's disease. Since both amantadine and memantine are chemically similar adamantane derivatives, memantine also exerts antiviral effects as previously reported.²⁹ Presumably, these effects could be a collective outcome of activities on host cell glutamate receptors and viral proteins like M2-viroprotein.³⁰

Novel NMDA receptor modulators

In recent years, a variety of NMDA receptor modulators have been identified, and they exhibit a broad spectrum of subunit selectivity and mechanisms of action.^{31–35} These compounds have been largely studied for their activities in neuronal NMDA receptor populations, with the aim of developing treatments for neurological and psychiatric disorders; however, these compounds and their analogs might have therapeutic potential for non-CNS disorders, but this has not yet been explored.

Through our ongoing NMDA receptor drug discovery project, we have identified a compound from PubChem (CID# 3794169), coded as CNS4, and studied its activity on NMDA receptors.³⁶ CNS4 selectively potentiates GluN1/2D receptor currents up to 8-fold, when activated by 100 μ M glycine and 0.3 μ M glutamate, and produces minimal effects on GluN1/2A or 1/2B receptors.³⁶ CNS4 has a variety of other biological activities as reported by the National Center for Advancing Translational Sciences (NCATS); for example: an inconclusive anti-viral activity against influenza-A virus non-structural protein-1 (PubChem AID# 2326); anti-malarial, as an inhibitor of apical membrane antigen-1 of *Plasmodium falciparum* (AID# 720542); antiprotozoal, as an inhibitor of fructose 1,6- biphosphate aldolase from *Giardia Lamblia* (AID# lamblia (2451); and inhibition of nuclear receptor ROR-gamma in the immune cells (AID# 2551 & 2546). The chemical structure of CNS4 and more details on its activities are available at [PubChem](#).

A multipronged approach to treat SARS

An NMDA receptor modulator with antiviral properties could serve as a novel treatment strategy for SARS. Potentiating NMDA receptor activity in the lung epithelial cells will increase calcium ion influx and promote downstream signaling mechanisms associated with cellular contractions that are possibly impaired during SARS. Pharmacological effects generated by triggering neuronal NMDA receptor function, coupled with concurrent potentiation of NMDA receptors expressed in the respiratory tract, could synergistically improve airway smooth muscle contractions. Further, a variety of neurological symptoms were clinically diagnosed in hospitalized COVID-19 patients.^{37,38} Neuropathogenesis could occur due to the neurologic injury resulting from systemic dysfunction,³⁹ dysregulated renin-angiotensin aldosterone system,⁴⁰ proinflammatory reactions,^{41,42} para-infectious and post-infectious triggers,⁴³ and direct viral invasion of the nervous system.^{44–46} As a well characterized neuropsychiatric drug target,⁴⁷ with the potential to improve lung function, NMDA receptors could be an ideal focal point for future pharmacological interventions of COVID-19. Clinical conditions involving hypoxia increase blood glutamate concentration by promoting transaminase activity that generates α -keto acids.^{48–50} Further, neuronal glutamate excitotoxicity induces paralysis in mice after infection by a human coronavirus.⁵¹ The connection between disruption in glutamate homeostasis and pathogenesis of various neurological and psychiatric disorders has been extensively studied in the past three decades. Therefore, optimizing glutamatergic signal transmission through neuronal and non-neuronal cell types, that express the major glutamate receptor subtypes like NMDA receptor, could be an appropriate strategy to reduce the extent of lung damage caused by SARS. In this perspective, compounds that modulate NMDA receptors based on glutamate concentration would be an ideal starting point for the development of a treatment approach involving modulation of glutamate signaling at both nerve cells and non-neuronal cells. CNS4 and other recently identified novel glutamate concentration biased NMDA receptor modulators^{34,35} could serve as lead candidates in the development of clinically useful compounds to treat COVID-19 or other SARS caused by various pathological conditions. Future studies should be carried out in this direction to test this hypothesis.

Conclusion

An increasing body of evidence suggests the expression of functional NMDA receptors in the lungs and their critical role in glutamate induced acute lung injury and acute respiratory distress syndrome.^{4,13,14,17–20} Despite its direct role in lung injury, little effort has been taken to develop NMDA receptor based therapeutic strategies for the treatment of lung diseases. With the revolution in glutamate receptor pharmacology in the past decade that yielded a variety of chemical tools to modulate NMDA receptors,^{31–36} and a COVID-19 pandemic that kills humans by primarily affecting lung function, this could be a suitable time to start working on a novel drug target for SARS treatment.

Data availability

No data is associated with this article.

Acknowledgements

Dr. Katherine Jamison is acknowledged for reading this article.

References

- Kim MS, Pinto SM, Getnet D, et al.: **A draft map of the human proteome.** *Nature*. 2014; **509**(7502): 575–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Traynelis SF, Wollmuth LP, McBain CJ, et al.: **Glutamate receptor ion channels: structure, regulation, and function.** *Pharmacol. Rev.* 2010; **62**(3): 405–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Paoletti P, Bellone C, Zhou Q: **NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.** *Nat. Rev. Neurosci.* 2013; **14**(6): 383–400.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dickman KG, Youssef JG, Mathew SM, et al.: **Ionotropic glutamate receptors in lungs and airways: molecular basis for glutamate toxicity.** *Am. J. Respir. Cell Mol. Biol.* 2004; **30**(2): 139–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Swanger SA, Traynelis SF: **Synaptic Receptor Diversity Revealed Across Space and Time.** *Trends Neurosci.* 2018; **41**(8): 486–8.
[PubMed Abstract](#) | [Publisher Full Text](#)

6. Deng A, Valdivielso JM, Munger KA, *et al.*: **Vasodilatory N-methyl-D-aspartate receptors are constitutively expressed in rat kidney.** *J. Am. Soc. Nephrol.* 2002; **13**(5): 1381–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Erdo SL: **Excitatory amino acid receptors in the mammalian periphery.** *Trends Pharmacol. Sci.* 1991; **12**(11): 426–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Genever PG, Wilkinson DJ, Patton AJ, *et al.*: **Expression of a functional N-methyl-D-aspartate-type glutamate receptor by bone marrow megakaryocytes.** *Blood.* 1999; **93**(9): 2876–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Gonzalez-Cadavid NF, Ryndin I, Vernet D, *et al.*: **Presence of NMDA receptor subunits in the male lower urogenital tract.** *J. Androl.* 2000; **21**(4): 566–78.
[PubMed Abstract](#)
10. Inagaki N, Kuromi H, Gono T, *et al.*: **Expression and role of ionotropic glutamate receptors in pancreatic islet cells.** *FASEB J.* 1995; **9**(8): 686–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Krizbai IA, Deli MA, Pestencz A, *et al.*: **Expression of glutamate receptors on cultured cerebral endothelial cells.** *J. Neurosci. Res.* 1998; **54**(6): 814–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Leung JC, Travis BR, Verlander JW, *et al.*: **Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system.** *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2002; **283**(4): R964–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Said SI: **Glutamate receptors and asthmatic airway disease.** *Trends Pharmacol. Sci.* 1999; **20**(4): 132–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Said SI, Dey RD, Dickman K: **Glutamate signalling in the lung.** *Trends Pharmacol. Sci.* 2001; **22**(7): 344–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Feldman JL, Windhorst U, Anders K, *et al.*: **Synaptic interaction between medullary respiratory neurones during apnoea induced by NMDA-receptor blockade in cat.** *J. Physiol.* 1992; **450**: 303–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Foutz AS, Champagnat J, Denavit-Saubie M: **Respiratory effects of the N-methyl-D-aspartate (NMDA) antagonist, MK-801, in intact and vagotomized chronic cats.** *Eur. J. Pharmacol.* 1988; **154**(2): 179–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Said SI, Dickman KG: **Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide.** *Regul. Pept.* 2000; **93**(1–3): 21–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Said SI, Pakbaz H, Berisha HI, *et al.*: **NMDA receptor activation: critical role in oxidant tissue injury.** *Free Radic. Biol. Med.* 2000; **28**(8): 1300–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Liao Z, Zhou X, Luo Z, *et al.*: **N-Methyl-D-aspartate Receptor Excessive Activation Inhibits Fetal Rat Lung Development in vivo and In Vitro.** *Biomed. Res. Int.* 2016; **2016**: 5843981.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Wang Y, Yue S, Luo Z, *et al.*: **N-methyl-D-aspartate receptor activation mediates lung fibroblast proliferation and differentiation in hyperoxia-induced chronic lung disease in newborn rats.** *Respir. Res.* 2016; **17**(1): 136.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Jih TK: **Acute respiratory distress syndrome (ARDS) and severe acute respiratory syndrome (SARS): are we speaking different languages?.** *J. Chin. Med. Assoc.* 2005; **68**(1): 1–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Dong YN, Hsu FC, Koziol-White CJ, *et al.*: **Functional NMDA receptors are expressed by human pulmonary artery smooth muscle cells.** *Sci. Rep.* 2021; **11**(1): 8205.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Foutz AS, Champagnat J, Denavit-Saubie M: **N-methyl-D-aspartate (NMDA) receptors control respiratory off-switch in cat.** *Neurosci. Lett.* 1988; **87**(3): 221–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Anaparti V, Ilarraza R, Orihara K, *et al.*: **NMDA receptors mediate contractile responses in human airway smooth muscle cells.** *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2015; **308**(12): L1253–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Cull-Candy SG, Leszkiewicz DN: **Role of distinct NMDA receptor subtypes at central synapses.** *Sci. STKE.* 2004; **2004**(255): re16.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Chen N, Luo T, Raymond LA: **Subtype-dependence of NMDA receptor channel open probability.** *J. Neurosci.* 1999; **19**(16): 6844–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Erreger K, Dravid SM, Banke TG, *et al.*: **Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles.** *J. Physiol.* 2005; **563**(2): 345–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Blanpied TA, Clarke RJ, Johnson JW: **Amantadine inhibits NMDA receptors by accelerating channel closure during channel block.** *J. Neurosci.* 2005; **25**(13): 3312–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Brison E, Jacomy H, Desforges M, *et al.*: **Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus.** *J. Virol.* 2014; **88**(3): 1548–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Wanka L, Iqbal K, Schreiner PR: **The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.** *Chem. Rev.* 2013; **113**(5): 3516–604.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Monaghan DT, Irvine MW, Costa BM, *et al.*: **Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.** *Neurochem. Int.* 2012; **61**(4): 581–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Costa BM, Irvine MW, Fang G, *et al.*: **A novel family of negative and positive allosteric modulators of NMDA receptors.** *J. Pharmacol. Exp. Ther.* 2010; **335**(3): 614–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Mullasseril P, Hansen KB, Vance KM, *et al.*: **A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors.** *Nat. Commun.* 2010; **1**: 90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Perszyk R, Katzman BM, Kusumoto H, *et al.*: **An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups.** *Elife.* 2018; **7**.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Perszyk RE, Swanger SA, Shelley C, *et al.*: **Biased modulators of NMDA receptors control channel opening and ion selectivity.** *Nat. Chem. Biol.* 2020; **16**(2): 188–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Costa BM, Kwapisz LC, Mehrkens B, *et al.*: **A glutamate concentration-biased allosteric modulator potentiates NMDA-induced ion influx in neurons.** *Pharmacol. Res. Perspect.* 2021; **9**(5): e00859.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Pezzini A, Padovani A: **Lifting the mask on neurological manifestations of COVID-19.** *Nat. Rev. Neurol.* 2020; **16**(11): 636–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Mao L, Jin H, Wang M, *et al.*: **Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.** *JAMA Neurol.* 2020; **77**(6): 683–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Kanberg N, Ashton NJ, Andersson LM, *et al.*: **Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19.** *Neurology.* 2020; **95**(12): e1754–e1759.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Lei Y, Zhang J, Schiavon CR, *et al.*: **SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2.** *Circ. Res.* 2021; **128**(9): 1323–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Chen G, Wu D, Guo W, *et al.*: **Clinical and immunological features of severe and moderate coronavirus disease 2019.** *J. Clin. Invest.* 2020; **130**(5): 2620–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Huang C, Wang Y, Li X, *et al.*: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet.* 2020; **395**(10223): 497–506.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Zhao H, Shen D, Zhou H, *et al.*: **Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?.** *The Lancet Neurology.* 2020; **19**(5): 383–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Song E, Zhang C, Israelow B, *et al.*: **Neuroinvasion of SARS-CoV-2 in human and mouse brain.** *bioRxiv: the preprint server for biology.* 2020.
45. Meinhardt J, Radke J, Dittmayer C, *et al.*: **Olfactory transmuscular SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19.** *Nat. Neurosci.* 2021; **24**(2): 168–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Matschke J, Lütgehetmann M, Hagel C, *et al.*: **Neuropathology of patients with COVID-19 in Germany: a post-mortem case series.**

- The Lancet Neurology*. 2020; **19**(11): 919–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Zhou Q, Sheng M: **NMDA receptors in nervous system diseases**. *Neuropharmacology*. 2013; **74**: 69–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Bai W, Li W, Ning YL, *et al.*: **Blood Glutamate Levels Are Closely Related to Acute Lung Injury and Prognosis after Stroke**. *Front. Neurol*. 2017; **8**: 755.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. Kumazawa K, Ibara S, Kobayashi K, *et al.*: **Changes of blood glutamate levels in hypoxic ischemic encephalopathy patients undergoing brain hypothermia**. *Hypothermia for Acute Brain Damage: Pathomechanism and Practical Aspects*. 2004; 320–24.
[Publisher Full Text](#)
 50. Gray LR, Tompkins SC, Taylor EB: **Regulation of pyruvate metabolism and human disease**. *Cell. Mol. Life Sci*. 2014; **71**(14): 2577–604.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Brison E, Jacomy H, Desforgues M, *et al.*: **Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein**. *J. Virol*. 2011; **85**(23): 12464–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 12 December 2022

<https://doi.org/10.5256/f1000research.77586.r157840>

© 2022 Ko J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jaewon Ko

Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea

This short article states that modulation of an NMDA receptor (NMDAR) function with anti-viral properties could be beneficial for treating disorders that involve NMDAR dysfunctions. The author first summarized known facts for distinct NMDAR subunits expressed in lung cells (i.e., expression levels and kinetics). The author then introduced amantadine (a potent NMDAR antagonist) and its analog (memantine) that have been clinically used for treatment of dyskinesia patients. The author also detailed a novel NMDAR modulator (i.e., CNS4) that has a possibly therapeutic potential for non-CNS disorders and SARS.

I believe that the author has done a wonderful job in concisely providing a logical opinion: a newly developed NMDAR modulator could be clinically promising for treating various non-neurological disorders that are linked to NMDAR dysfunctions.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Synaptic neuroscience.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 25 July 2022

<https://doi.org/10.5256/f1000research.77586.r142691>

© 2022 Pearle J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

James Pearle

California Research Medical Group, Fullerton, USA

In severe acute respiratory distress syndrome, cellular contractions may be disrupted.

By triggering glutamate receptor function in the brain and with stimulation of the respiratory tract, a synergetic effect may improve airways smooth muscle function and neurologic function.

Stimulation of NMDA receptors in the brain and in the airway muscles could be beneficial in the treatment of severe respiratory distress syndrome and associated neurologic disease.

The authors excellently outline how an NMDA receptor modulator with antiviral properties could be a novel treatment strategy for SARS.

This avenue of treatment has the potential to prevent or treat the neurological dysfunction often associated with SARS.

At the same time, NMDA receptor modulation may improve pulmonary status by improving smooth muscle airways function, often disrupted in this syndrome.

The multifaceted potential benefits of stimulating glutamate receptors could involve both the lungs and the nervous system.

The authors have clearly and concisely outlined the rationale and hypothesis for the use of NMDA modulators in the treatments of SARS and associated neurologic dysfunction.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pulmonologist

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research